Literature DB >> 21295174

Effectiveness of serial increases in amino-terminal pro-B-type natriuretic peptide levels to indicate the need for mechanical circulatory support in children with acute decompensated heart failure.

Derek T H Wong1, Kristen George, Judith Wilson, Cedric Manlhiot, Brian W McCrindle, Khosrow Adeli, Paul F Kantor.   

Abstract

We sought to determine prospectively whether serial assessment of the natriuretic peptide prohormone, amino-terminal pro-B-type natriuretic peptide (NT-pro-BNP), correlated with clinical severity and outcomes in children hospitalized for acute decompensated heart failure (ADHF). Patients (>1 month of age) admitted from 2005 to 2007 with ADHF requiring intravenous vasoactive/diuretic therapy for ADHF were eligible. Serum NT-pro-BNP levels were obtained within 24 hours of admission and at prespecified intervals, and clinical caregivers were blinded to these levels. End points included hospital discharge, death or cardiac transplantation, and care escalation including the need for mechanical circulatory support (MCS) was noted. Twenty-four patients were enrolled: 22 survived to hospital discharge and 2 died. Ten required MCS (of which 6 underwent cardiac transplantation). Two patients underwent transplantation without MCS. For the entire cohort, NT-pro-BNP levels peaked at days 2 to 3 after admission, with a subsequent gradual decrease until discharge. However, for those who did require MCS, NT-pro-BNP failed to decrease consistently until after MCS initiation. At discharge, NT-pro-BNP levels were significantly decreased from admission levels but remained well above normal for all patients. Single-point NT-pro-BNP levels on admission did not correlate with independently assessed clinical scores of heart failure severity or predict the need for MCS in this cohort. In conclusion, serial NT-pro-BNP levels demonstrated an incremental trend after 48 hours in patients who went on to require MCS but decreased in all other patients and may therefore assist the decision to initiate or avoid MCS after admission for pediatric ADHF.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21295174     DOI: 10.1016/j.amjcard.2010.10.015

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision.

Authors:  Robert D Ross
Journal:  Pediatr Cardiol       Date:  2012-04-05       Impact factor: 1.655

2.  Serial Measurement of Amino-Terminal Pro-B-Type Natriuretic Peptide Predicts Adverse Cardiovascular Outcome in Children With Primary Myocardial Dysfunction and Acute Decompensated Heart Failure.

Authors:  Shivanand Shankar Medar; Daphne T Hsu; H Michael Ushay; Jacqueline M Lamour; Hillel W Cohen; James S Killinger
Journal:  Pediatr Crit Care Med       Date:  2015-07       Impact factor: 3.624

3.  Current applications and Future Needs for Biomarkers in Pediatric Cardiomyopathy and Heart Failure: Summary From The Second International Conference On Pediatric Cardiomyopathy.

Authors:  Paul F Kantor; Paolo Rusconi; Steven Lipshultz; Seema Mital; James D Wilkinson; Michael Burch
Journal:  Prog Pediatr Cardiol       Date:  2011-08-01

4.  Pediatric and adult dilated cardiomyopathy are distinguished by distinct biomarker profiles.

Authors:  Kory J Lavine; Kathleen E Simpson; Melanie R F Gropler; Steven E Lipshultz; James D Wilkinson; Jeffrey A Towbin; Steven D Colan; Charles E Canter
Journal:  Pediatr Res       Date:  2021-08-17       Impact factor: 3.953

5.  Clinical Research on Brain Natriuretic Peptide Guiding the Application of β1 Receptor Blocker in Patients with Moderate to Severe Heart Failure.

Authors:  Jiang-Jin Li; Xiao-Li Xiang; Xiao-Yi Tian; Ya-Fei Shi
Journal:  Acta Cardiol Sin       Date:  2015-01       Impact factor: 2.672

6.  Usefulness of amino terminal pro-B-type natriuretic peptide in evaluating children with cardiac failure.

Authors:  Isoken A Isah; Wilson E Sadoh; Nosakhare J Iduoriyekemwen
Journal:  Cardiovasc Diagn Ther       Date:  2017-08

Review 7.  The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update.

Authors:  Massimiliano Cantinotti; Yuk Law; Simona Vittorini; Maura Crocetti; Marotta Marco; Bruno Murzi; Aldo Clerico
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

Review 8.  Pediatric heart failure: current state and future possibilities.

Authors:  Joseph W Rossano; Gi Young Jang
Journal:  Korean Circ J       Date:  2015-01-26       Impact factor: 3.243

Review 9.  The under reporting of recruitment strategies in research with children with life-threatening illnesses: A systematic review.

Authors:  Briony F Hudson; Linda Jm Oostendorp; Bridget Candy; Victoria Vickerstaff; Louise Jones; Monica Lakhanpaul; Myra Bluebond-Langner; Paddy Stone
Journal:  Palliat Med       Date:  2016-09-08       Impact factor: 4.762

10.  Diagnostic Accuracy of NT-ProBNP for Heart Failure with Sepsis in Patients Younger than 18 Years.

Authors:  Chun-Wang Lin; Wen Tang; Fang Wen; Jin-Jin Chen; Xiang-Lin Zeng; Zong-Geng Chen
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.